Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DAWN 
Day One Biopharmaceuticals Inc (DAWN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: DAWN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $24.25
1 Year Target Price $24.25
| 4 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -49.37% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 729.32M USD | Price to earnings Ratio - | 1Y Target Price 24.25 |
Price to earnings Ratio - | 1Y Target Price 24.25 | ||
Volume (30-day avg) 8 | Beta -1.25 | 52 Weeks Range 5.63 - 16.76 | Updated Date 09/14/2025 |
52 Weeks Range 5.63 - 16.76 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -50.63% | Operating Margin (TTM) -103.14% |
Management Effectiveness
Return on Assets (TTM) -15.19% | Return on Equity (TTM) -24.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 279215362 | Price to Sales(TTM) 3.89 |
Enterprise Value 279215362 | Price to Sales(TTM) 3.89 | ||
Enterprise Value to Revenue 1.49 | Enterprise Value to EBITDA -7.18 | Shares Outstanding 102432000 | Shares Floating 78723038 |
Shares Outstanding 102432000 | Shares Floating 78723038 | ||
Percent Insiders 16.94 | Percent Institutions 85.75 |
Upturn AI SWOT
Day One Biopharmaceuticals Inc
Company Overview
History and Background
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for children and adults with cancer. It was founded to address the unmet need in pediatric oncology.
Core Business Areas
- Oncology Drug Development: Focuses on the discovery, development, and commercialization of new therapies for pediatric and adult cancers. Specializing in precision medicine approaches and targeted therapies.
Leadership and Structure
The leadership team consists of experienced executives with backgrounds in biopharmaceutical development, commercialization, and finance. The organizational structure includes departments focused on research, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Tovorafenib: An oral brain-penetrant RAF kinase inhibitor. Being developed for relapsed pediatric low-grade glioma (pLGG) and other tumors. Primary competitor includes existing chemotherapy regimens (e.g., carboplatin, vincristine).
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the oncology segment, is experiencing growth due to an aging population and advancements in targeted therapies. The pediatric oncology market represents a significant unmet need.
Positioning
Day One Biopharmaceuticals is positioned as a precision medicine company specializing in targeted therapies for cancers with unmet needs, specifically pediatric low-grade glioma.
Total Addressable Market (TAM)
The pediatric low-grade glioma (pLGG) market is estimated to be significant, with potential for expansion into other RAF-altered tumors. Market size can be further quantified when tovorafenib is approved and further adopted. Day One Biopharmaceuticals is positioned to capture a sizable share of this market with the launch of tovorafenib.
Upturn SWOT Analysis
Strengths
- Targeted therapies focus
- Strong clinical pipeline
- Experienced management team
- Breakthrough Therapy Designation for Tovorafenib
Weaknesses
- Limited commercialized products
- Reliance on clinical trial success
- High R&D costs
Opportunities
- Expansion of product pipeline
- Partnerships and collaborations
- Potential for regulatory approvals in multiple indications
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- MRTX
- NKTR
- GILD
Competitive Landscape
Day One Biopharmaceuticals competes with larger pharmaceutical companies and smaller biotechnology firms in the oncology space. Its competitive advantage lies in its focus on precision medicine and targeted therapies.
Growth Trajectory and Initiatives
Historical Growth: As a relatively new company, historical growth has been primarily driven by progress in the clinical pipeline.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals, particularly for Tovorafenib. Analysts' estimates vary based on projected market penetration and pricing.
Recent Initiatives: Recent strategic initiatives include advancing Tovorafenib through clinical trials and preparing for potential commercial launch.
Summary
Day One Biopharmaceuticals is a clinical-stage company with a focus on pediatric oncology, particularly low-grade glioma. The company's strength lies in its targeted therapies approach and clinical pipeline, most notably tovorafenib. Success hinges on favorable clinical trial outcomes and regulatory approvals. Financial stability and market competition pose challenges that must be addressed to sustain growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market information are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Day One Biopharmaceuticals Inc
Exchange NASDAQ | Headquaters Brisbane, CA, United States | ||
IPO Launch date 2021-05-27 | CEO, President & Director Dr. Jeremy Bender M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 182 | Website https://dayonebio.com |
Full time employees 182 | Website https://dayonebio.com | ||
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.